TITLE

Mutations in Clotting Factors and Inflammatory Bowel Disease

AUTHOR(S)
Bernstein, Charles N.; Sargent, Michael; Vos, Hans L.; Rosendaal, Frits R.
PUB. DATE
February 2007
SOURCE
American Journal of Gastroenterology;Feb2007, Vol. 102 Issue 2, p338
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Patients with Crohn's disease (CD) and ulcerative colitis (UC) have a three- to fourfold greater risk of venous thrombosis compared with the general population. We aimed to determine if patients with CD and UC had a greater likelihood of mutations in genes that increase clotting risk, in a population-based case–control study. METHODS: Subjects were drawn from the University of Manitoba IBD Research Registry and controls were drawn from Manitoba Health's administrative database. Cases (CD, N = 327; UC, N = 165) and controls (N = 412) underwent venipuncture. DNA was purified from whole blood. Genotypes for wild-type and common mutations that have been associated with venous thrombosis for each of Factor II (prothrombin) (G20210A), Factor V (G1691A:‘Leiden’), methylenetetrahydrofolate reductase (MTHFR, C677T), and Factor XIII (val34leu) were assessed. RESULTS: A total of 1.5% and 6.1% were heterozygous for Factor II and Factor V variants, respectively, without differences among cases and controls. Only one subject was homozygous for Factor V Leiden (and none were homozygous for Factor II mutation). Although some differences were observed among cases and controls in the prevalence of MTHFR C677T (decrease in mutant allele carriership in UC) and FXIII val34leu (increase in double mutant allele carriership in CD), these did not explain an excess risk of thrombosis. Age, sex, or disease phenotypes were not associated with prothrombotic genotypes. CONCLUSIONS: While there was a slightly greater prevalence of Factor XIII mutation carriership in CD, we did not find that gene mutations for these four common factors could explain the greater risk of venous thrombosis in CD and UC.
ACCESSION #
23774279

 

Related Articles

  • Prothrombotic Inherited Abnormalities Other Than Factor V Leiden Mutation Do Not Play a Role in Venous Thrombosis in Inflammatory Bowel Disease. Guédon, C.; Le Cam-Duchez, V.; Lalaude, O.; Ménard, J. F.; Lerebours, E.; Borg, J. Y. // American Journal of Gastroenterology;May2001, Vol. 96 Issue 5, p1448 

    OBJECTIVES: Because the incidence of thromboembolism is increased in patients with inflammatory bowel disease, we attempted to assess the role of prothrombotic inherited coagulation abnormalities in the development of thrombosis. METHODS: Four populations were compared: 15 patients with...

  • Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking. Whitwell, Sophia C. L.; Mathew, Christopher G.; Lewis, Cathryn M.; Forbes, Alastair; Watts, Sally; Sanderson, Jeremy; Hollands, Gareth J.; Prevost, A. Toby; Armstrong, David; Kinmonth, Ann Louise; Sutton, Stephen; Marteau, Theresa M. // BMC Public Health;2011, Vol. 11 Issue 1, p44 

    Background: Estimates of the risk of developing Crohn's disease (CD) can be made using DNA testing for mutations in the NOD2 (CARD15) gene, family history, and smoking status. Smoking doubles the risk of CD, a risk that is reduced by stopping. CD therefore serves as a timely and novel paradigm...

  • Assessment of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels in Inflammatory Bowel Diseases. Saibeni, S.; Bottasso, B.; Spina, L.; Bajetta, M.; Danese, S.; Gasbarrini, A.; de Franchis, R.; Vecchi, M. // American Journal of Gastroenterology;Oct2004, Vol. 99 Issue 10, p1966 

    OBJECTIVES: Hypofibrinolysis has been proposed as a possible mechanism underlying the known risk of thrombosis observed in patients with inflammatory bowel diseases (IBD). Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis. Increased TAFI plasma...

  • Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. Liang, Jie; Wu, Shengjun; Feng, Bin; Lei, Shaoni; Luo, Guanhong; Wang, Jingbo; Li, Kai; Li, Xiaohua; Xie, Huahong; Zhang, Dexin; Wang, Xin; Wu, Kaichun; Miao, Danmin; Fan, Daiming // Journal of Gastroenterology;Oct2011, Vol. 46 Issue 10, p1158 

    Background: Recent studies proved that inflammatory bowel disease (IBD) patients had a higher risk of thromboembolism and a Factor V Leiden mutation that prevents the efficient inactivation of factor V, which leads to thromboembolism and thus contributes to a high potential risk of IBD. However,...

  • Unraveling the Mechanisms of Thrombosis in Inflammatory Bowel Disease. Koutroubakis, Loannis E. // American Journal of Gastroenterology;May2001, Vol. 96 Issue 5, p1325 

    Introduces the article "Prothrombotic Inherited Abnormalities Other Than Factor V Leiden Mutation Do Not Play a Role in Venous Thrombosis in Venous Thrombosis in Inflammatory Bowel Disease,"by C. Guédon, V. Le Cam-Duchez, O. Lalaude, J. F. Ménard, E. Lerebours and J. Y. Borg.

  • The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. Genua, Marco; Rutella, Sergio; Correale, Carmen; Danese, Silvio // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    The Triggering Receptors Expressed on Myeloid cells (TREM) are a family of cell-surface molecules that control inflammation, bone homeostasis, neurological development and blood coagulation. TREM-1 and TREM-2, the best-characterized receptors so far, play divergent roles in several infectious...

  • Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Scaldaferri, Franco; Sans, Miquel; Vetrano, Stefania; Graziani, Cristina; de Cristofaro, Raimondo; Gerlitz, Bruce; Repici, Alessandro; Arena, Vincenzo; Malesci, Alberto; Panes, Julian; Grinnell, Brian W.; Danese, Silvio // Journal of Clinical Investigation;Jul2007, Vol. 117 Issue 7, p1951 

    Endothelial protein C receptor (EPCR) and thrombomodulin (TM) are expressed at high levels in the resting microvasculature and convert protein C (PC) into its activated form, which is a potent anticoagulant and antiinflammatory molecule. Here we provide evidence that in Crohn disease (CD) and...

  • seroenteritis.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2105 

    A definition of the term "seroenteritis" which refers to an inflammation of the serous layer of the intestine is presented.

  • Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. Rapozo, Davy Carlos Mendes; Grinmann, Ana Braunstein; Carvalho, Ana Teresa Pugas; de Souza, Heitor Siffert P.; Soares-Lima, Sheila Coelho; Simão, Tatiana de Almeida; de Paiva, Daurita; Abby, Flávio; Albano, Rodolpho Mattos; Pinto, Luiz Felipe Ribeiro // International Journal of Colorectal Disease;Oct2009, Vol. 24 Issue 10, p1141 

    Patients with ulcerative colitis (UC) and Crohn's disease (CD) have a high risk for colorectal cancer (CRC). To understand the molecular basis of colitis-associated CRC, we analyzed alterations in TP53, APC, K-ras, and DCC genes in the non-dysplastic UC and CD colon. Endoscopic biopsies were...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics